The EIB lent 20 million EUR to a Swedish biotechnology company.

Sources

• PrimaryEuropean Investment Bank - Press ReleaseEIB backs Swedish biotech scale-up BioLamina with €20 million to enable stem cell technologies targeting diseases such as type 1 diabetes, Parkinson's disease, heart failure, acute liver failure and cancer
• PrimaryEuropean Investment Bank - Project Sheet20 million EIB financing to BioLamina, Release date 20 April 2026, Signed 14/04/2026
• SecondaryEU-StartupsStockholm's BioLamina secures €20 million EIB loan, Cell therapies can be used to target conditions such as type 1 diabetes, Parkinson's disease, heart failure
• SecondaryThe Brussels TimesSwedish biotech BioLamina secures €20m EIB loan to scale cell therapy materials, targeting conditions including type 1 diabetes, Parkinson's disease, heart failure